How Raman Spectroscopy Is Benefitting Developing And Developed Countries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

How Raman Spectroscopy Is Benefitting Developing And Developed Countries


Pharmaceutical Technology Europe
Volume 22, Issue 7

The dangers in developed countries

Although supply chains in developed regions, such as the EU and the US, are tighter than those in less developed countries, they are still not 100% secure against counterfeiters, which is why it is still necessary for manufacturers in these areas to implement anti-counterfeiting strategies. Counterfeit identification rates will be lower in these regions compared with less developed countries, but every case counts. The biggest risk in these countries lies in medicine purchases made via the internet. As such, it is very important to educate consumers to allow them to better tell whether the medicine they are buying is legitimate. There are little things consumers can do to check the medicine they are taking is authentic, such as checking the seal to confirm it's not broken, reviewing the expiration date and buying medicines only from legal pharmacies.

Another significant risk facing developed countries stems from globalisation. Many businesses outsource the manufacture of drugs or raw materials to foreign countries, which creates the potential for substandard or counterfeit products and ingredients to enter the supply chain. One example of this is the 2008 Heparin incident when it was discovered that Heparin, which is used daily in many hospitals worldwide, was contaminated with a toxic substance. The contamination occurred in China and resulted in hundreds of patient injuries and more than 80 deaths.

The FDA and the European Medicines Agency rely on manufacturers to meet certain standards, but many medicines now have foreign sources beyond the reach of these agencies. This situation will not be resolved unless new policies and regulations are put in place.

Counterfeiters will inevitably focus on products that are easiest to counterfeit, as well as the countries with the least amount of enforcement. The challenge for manufacturers is to keep pace with counterfeiters by making it as difficult as possible for drugs to be copied. This will be achieved by deploying serialisation technologies, such as RFID, as well as chemical identification instruments that can provide a quick "pass" or "fail" analysis of a medicine on the spot.

Duane Sword is Vice President Marketing & International Sales at Thermo Fisher Scientific.

References

1. RFID Journal, "Pfizer's RFID Pilot Is the Start of Something Big" (2006). http://www.rfidjournal.com/

2. Federal Communications Commission, "Radio Frequency Safety" (2009). http://www.fcc.gov/

3. Thermo Fisher Scientific, "Thermo Fisher Scientific Helps Nigerian FDA Fight Counterfeit and Substandard Pharmaceuticals Using State-of-the-Art Portable Raman Instrument" (2010). http://www.ahurascientific.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here